{"nctId":"NCT00621504","briefTitle":"Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia","startDateStruct":{"date":"2008-01"},"conditions":["Bacterial Pneumonia"],"count":606,"armGroups":[{"label":"Ceftaroline fosamil for Injection","type":"EXPERIMENTAL","interventionNames":["Drug: Ceftaroline fosamil for Injection","Drug: Clarithromycin"]},{"label":"IV Ceftriaxone","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: IV Ceftriaxone","Drug: Placebo","Drug: Clarithromycin"]}],"interventions":[{"name":"Ceftaroline fosamil for Injection","otherNames":[]},{"name":"IV Ceftriaxone","otherNames":["Ceftriaxone"]},{"name":"Placebo","otherNames":[]},{"name":"Clarithromycin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nSubjects are required to meet the following inclusion criteria:\n\n* Community-acquired pneumonia\n* initial hospitalization, or treatment in an emergency room or urgent care setting\n* infection would require initial treatment with IV antimicrobials.\n\nExclusion Criteria:\n\nSubjects must NOT meet any of the following exclusion criteria:\n\n* CAP suitable for outpatient therapy with an oral antimicrobial agent\n* respiratory tract infections not due to community-acquired bacterial\n* Non-infectious causes of pulmonary infiltrates\n* Pleural empyema\n* Infection with an atypical organism\n* History of any hypersensitivity or allergic reaction to any ÃŸ-lactam antimicrobial\n* History of any hypersensitivity or allergic reaction to clarithromycin or any macrolide/ ketolide","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Clinical Cure Rate at Test-of-Cure (TOC) in the Modified Intent-to-Treat Efficacy (MITTE) Populations","description":"Cure:Total resolution of all signs and symptoms of pneumonia (ie,CABP), or improvement to such an extent that further antimicrobial therapy was not necessary\n\nFailure: Any of the following:\n\n* Persistence, incomplete clinical resolution, or worsening in signs and symptoms of CABP that required alternative antimicrobial therapy\n* Treatment-limiting adverse event (AE) leading to discontinuation of study drug therapy, when subject required alternative antimicrobial therapy to treat the pneumonia\n* Death wherein pneumonia (ie,CABP) was considered causative\n\nIndeterminate: Inability to determine an outcome","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"244","spread":null},{"groupId":"OG001","value":"233","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Clinical Response at End of Therapy (EOT)","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Microbiological Success Rate at Test of Cure (TOC)","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Overall (Clinical and Radiographic) Success Rate at Test of Cure (TOC)","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Clinical and Microbiological Response by Pathogen at TOC","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Clinical Relapse at Late Follow Up (LFU)","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"PRIMARY","title":"Clinical Cure Rate for Ceftaroline Compared to That for Ceftriaxone at Test-of-Cure (TOC) in the Clinically Evaluable (CE) Population","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Microbiological Re-infection/Recurrence at LFU","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Evaluate Safety","description":null,"paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":28,"n":298},"commonTop":["Diarrhea","Nausea","Insomnia","Headache","Hypertension"]}}}